Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
External beam radiotherapy · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| External beam radiotherapy | PROCEDURE | - |
Inclusion Criteria: * Histologically proven small cell lung cancer * Age equal to or greater than 18 years * Good performance status * Signed study consent form Exclusion Criteria: * Patients who have undergone resection * Wrong histology * Previous thoracic/neck radiotherapy * Prior chemotherapy...
External beam radiotherapy is being studied for use in Carcinoma, Small Cell, specifically in the context of limited stage small cell lung cancer. It is delivered concurrently with chemotherapy as part of a Phase 1 clinical trial. The treatment is intended for patients aged 18 years and older.
External beam radiotherapy is being developed by Avalon GloboCare Corp., a company listed on the stock exchange under the ticker symbol ALBT. The company is conducting clinical research on this treatment approach for small cell carcinoma.
External beam radiotherapy is currently in Phase 1 of clinical development. It is an investigational treatment and has not yet been approved by regulatory authorities. The Phase 1 trial has been completed, with a total enrollment of 18 participants.
External beam radiotherapy has been studied in one clinical trial, identified by the NCT number NCT00126828. This Phase 1 trial, titled 'Study of Radiation Dose Intensity Concurrent With Chemotherapy For Limited Stage Small Cell Lung Cancer,' was conducted in Canada and has been completed.
External beam radiotherapy is a form of radiation therapy that delivers radiation from outside the body to target tumors. In the context of this clinical trial, it is being used in combination with chemotherapy for the treatment of limited stage small cell lung cancer.